Clinical Trial Update: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor [Phase 2]

View source ↗

Summary

The Phase 2 study of famitinib in advanced or metastatic gastroenteropancreatic neuroendocrine tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Famitinib (Famitinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Gastroenteropancreatic Neuroendocrine Tumor | Phase 2 | Status: TERMINATED